Clinical trial
Effect of Ranibizumab on Malignant Conjunctival Neoplasia
NCT00456495 · The New York Eye Cancer Center, Other · Completed
Key facts
| NCT number | NCT00456495 |
|---|---|
| Title | Effect of Ranibizumab on Malignant Conjunctival Neoplasia |
| Official title | Effect of Ranibizumab on Malignant Conjunctival Neoplasia |
| Lead sponsor | The New York Eye Cancer Center, Other |
| Collaborators | Genentech, Inc. Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Conjunctival Neoplasms |
| Intervention type | Drug |
| Interventions | ranibizumab |
| Enrollment | 5 |
| Start date | Mar 1, 2007 |
| Primary completion | Sep 1, 2010 |
| Completion | Sep 1, 2010 |
| First posted | Apr 5, 2007 |
| Last update posted | Jul 21, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: